SCP Stock Overview A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Scancell Holdings plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Scancell Holdings Historical stock prices Current Share Price UK£0.092 52 Week High UK£0.23 52 Week Low UK£0.071 Beta 0.42 1 Month Change -7.07% 3 Month Change -25.20% 1 Year Change 1.66% 3 Year Change -61.02% 5 Year Change 38.55% Change since IPO -76.59%
Recent News & Updates
Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £1 million. Dec 10 Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £1 million.
Scancell Holdings plc Announces Further Positive Data from the Ongoing SCOPE Trial of SCIB1 with Double CPIs for Advanced Melanoma Nov 19 Scancell Holdings plc Announces CEO Changes
Scancell Holdings plc, Annual General Meeting, Oct 25, 2024 Oct 01
Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024 Sep 18 See more updates
Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £1 million. Dec 10 Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £1 million.
Scancell Holdings plc Announces Further Positive Data from the Ongoing SCOPE Trial of SCIB1 with Double CPIs for Advanced Melanoma Nov 19 Scancell Holdings plc Announces CEO Changes
Scancell Holdings plc, Annual General Meeting, Oct 25, 2024 Oct 01
Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024 Sep 18
New minor risk - Financial data availability Sep 16 Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial
Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study Jul 24
Scancell Holdings plc Appoints Florian Reinaud to the Board Jul 10
New minor risk - Shareholder dilution Jul 07
New minor risk - Market cap size Jun 11
New minor risk - Market cap size Apr 17
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board Mar 15
Scancell Holdings plc Directorate and Executive Changes Changes Feb 05
Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024 Jan 26
Scancell Holdings plc Announces Update on SCOPE Trial Jan 18 Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million. Dec 20
Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million. Dec 02
Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million. Dec 01
Scancell Holdings plc, Annual General Meeting, Nov 29, 2023 Nov 01
Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023 Oct 05
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free Sep 29
Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma Sep 20
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1 Sep 14
Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development Sep 08
Scancell Appoints Sath Nirmalananthan as CFO Aug 29
New minor risk - Financial data availability Jul 28
New minor risk - Market cap size Jul 18
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 12
Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1 Jul 11
Scancell Holdings plc Announces Positive Response in Covidity Trial Feb 13
Scancell Holdings plc Announces Executive Changes Feb 01
Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023 Jan 18
Less than half of directors are independent Nov 16
Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify Nov 01
Scancell Holdings plc, Annual General Meeting, Nov 21, 2022 Oct 30
Scancell Holdings plc Announces Board Changes Oct 26
Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial Aug 17
Scancell Holdings plc to Produce TCB Antibodies Jun 23
Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial Jun 15
Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital Jun 13
Less than half of directors are independent Apr 27
Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment Apr 11
Scancell Holdings plc Announces Update on Covidity Clinical Trial Mar 29
Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa Jan 31
Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1 Aug 27
CEO & Director Clifford Holloway has left the company Aug 04
Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine Jun 22
New 90-day high: €0.35 Feb 16
Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK Feb 03
Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director Nov 18
Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020 Oct 05
Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine Oct 02 Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited
Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million. Aug 12 Shareholder Returns SCP DE Biotechs DE Market 7D -5.6% 2.5% -0.4% 1Y 1.7% -10.2% 7.9%
See full shareholder returns
Return vs Market: SCP underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is SCP's price volatile compared to industry and market? SCP volatility SCP Average Weekly Movement 25.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SCP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SCP's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.
Show more Scancell Holdings plc Fundamentals Summary How do Scancell Holdings's earnings and revenue compare to its market cap? SCP fundamental statistics Market cap €114.91m Earnings (TTM ) -€7.07m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SCP income statement (TTM ) Revenue UK£0 Cost of Revenue UK£0 Gross Profit UK£0 Other Expenses UK£5.86m Earnings -UK£5.86m
Last Reported Earnings
Apr 30, 2024
Earnings per share (EPS) -0.0063 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -541.3%
How did SCP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 11:42 End of Day Share Price 2025/01/03 00:00 Earnings 2024/04/30 Annual Earnings 2024/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Scancell Holdings plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Navid Malik Cavendish Historical (Cenkos Securities) Dr Julie Panmure Liberum Julie Simmonds Panmure Liberum
Show 2 more analysts 
